Table 1 Features of the early-onset PSD and non-PSD patient populations.

From: Association of higher triglyceride glucose index and triglyceride to high density lipoprotein cholesterol ratio with early-onset post-stroke depression

Variable

Non-PSD (n = 336)

PSD (n = 206)

T/Z

P

ES

Demographic characteristics

 Age, years

67.11 ± 11.26

63.52 ± 11.62

-3.546

< 0.001

0.832

 Male, n (%)

202(60.12)

124(60.19)

0.098

0.986

0.091

 BMI, kg/m2

23.71 ± 3.35

23.35 ± 3.43

1.915

0.113

0.105

Vascular risk factors, n (%)

 Hypertension

268(79.76)

174(84.47)

1.878

0.171

0.089

 Diabetes mellitus

87(25.89)

56(27.18)

0.110

0.740

0.091

 Coronary artery disease

69(20.53)

30(14.56)

3.051

0.081

0.112

 Current smoking

147(43.75)

84(40.78)

0.462

0.497

0.089

 Current drinking

91(27.08)

51(24.76)

0.357

0.550

0.072

Lesion location, n (%)

 Frontal lobe

24(7.14)

17(8.25)

0.225

0.635

0.110

 Temporal lobe

11(3.27)

8(3.88)

0.140

0.708

0.915

 Parietal lobe

27(8.03)

17(8.25)

0.008

0.929

0.150

 Occipital lobe

11(3.27)

6(2.91)

0.055

0.815

0.124

 Basal ganglia

138(41.07)

85(41.26)

0.002

0.965

0.094

 Thalamus

23(6.85)

13(6.31)

0.059

0.808

0.114

 Brainstem

70(20.83)

48(23.30)

0.457

0.499

0.092

 Cerebellum

32(9.52)

16(7.77)

0.488

0.485

0.063

Major vascular territories

  

0.462

0.794

0.029

 Anterior circulation

201(59.82)

124(60.19)

   

 Posterior circulation

118(35.12)

69(33.50)

   

 Both

17(5.06)

13(6.31)

   

Stroke subtype, n (%)

  

0.553

0.968

0.170

 LAA

88(26.19)

56(27.18)

   

 SAO

154(45.83)

97(47.09)

   

 CE

62(18.45)

37(17.96)

   

 SOE

14(4.17)

7(3.40)

   

 SUE

18(5.36)

9(4.37)

   

Medication use history, n (%)

 Previous antiplatelet

48(16.13)

25(12.14)

0.506

0.477

0.112

 Previous statin

38(11.31)

26(12.61)

0.211

0.646

0.108

 Previous antihypertension

244(72.62)

155(75.24)

0.453

0.501

0.159

 Previous hypoglycemic agents

80(23.81)

50(24.27)

0.015

0.903

0.083

Neuropsychological evaluation

 NIHSS score, median (IQR)

2(0–3)

2(1–4)

-2.839

0.006

0.554

 mRS score, median (IQR)

1(1–2)

2(1–3)

-3.936

< 0.001

0.659

 HAMD-17score, median (IQR)

4(3–6)

15(11–19)

-15.647

< 0.001

0.454

Laboratory data

 WBC (× 109/L)

6.74 ± 1.96

6.87 ± 1.99

-0.764

0.445

0.231

 Platelets (× 1012/L)

210.42 ± 63.78

212.39 ± 66.28

-1.034

0.301

0.195

 Neutrophils (× 109/L)

5.98 ± 1.70

6.08 ± 1.73

-1.303

0.193

0.224

 Lymphocytes (× 109/L)

1.69 ± 0.67

1.72 ± 0.64

-1.296

0.062

0.184

 Monocytes (× 109/L)

0.41 ± 0.19

0.40 ± 0.16

1.549

0.091

0.114

 Cr (µmol/L)

74.40 ± 35.45

77.24 ± 32.37

0.947

0.344

0.201

 UA (µmol/L)

323.23 ± 90.99

336.15 ± 97.71

-1.544

0.123

0.198

 FBG (mmol/L)

4.7(4.26–5.32)

6.19(4.99–8.65)

-5.048

0.002

0.458

 TG (mmol/L)

1.21(0.97–1.58)

2.34(1.69–3.38)

-7.528

< 0.001

0.479

 TC (mmol/L)

4.49(3.43–4.86)

4.52(3.82–5.24)

-0.873

0.254

0.116

 HDL-C (mmol/L)

1.06 ± 0.25

0.95 ± 0.27

4.429

< 0.001

0.895

 LDL-C (mmol/L)

2.70 ± 0.78

2.72 ± 0.90

-0.713

0.195

0.221

 TyG index

6.73(6.35–7.00)

7.79(7.44–8.22)

-8.064

< 0.001

0.794

 TG/HDL-C ratio

1.11(0.85–1.67)

2.39(1.77–3.95)

-5.976

< 0.001

0.515

  1. TyG index, triglyceride–glucose index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; FBG, fasting blood glucose; UA, Uric acid; Cr, creatinine; WBC, white blood cell; SUE, stroke of undetermined etiology; SOE, stroke of other determined etiology; CE, cardioembolism; SAO, small-artery occlusion; LAA, large-artery atherosclerosis; HAMD-17, Hamilton depression scale 17 items; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; ES, effect size.
Back to article page